Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210
AssigneeMillennium Pharmaceuticals, Inc.
InventorsThomas Joseph Logan, Miyoung Chun
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsThomas Joseph Logan, Miyoung Chun
Estimating the term…
The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
A method for identifying a compound capable of treating a cardiovascular disorder. comprising assaying the ability of the compound to modulate 1419, 58765 or 2210 nucleic acid expression or 1419, 58765 or 2210 polypeptide activity, thereby identifying a compound capable of treating a cardiovascular disorder.
A method for identifying a compound capable of modulating lipid production comprising:
A method for modulating lipid production in a cell comprising contacting a cell with a 1419, 58765 or 2210 modulator. thereby modulating lipid production in the cell.
A method for treating a subject having a cardiovascular disorder characterized by aberrant 1419, 58765 or 2210 polypeptide activity or aberrant 1419, 58765 or 2210 nucleic acid expression comprising administering to the subject a 1419, 58765 or 2210 modulator, thereby treating said subject having a cardiovascular disorder.
Dependencies are inferred from the claim text.